{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gene+Expression&page=4", "query": { "condition": "Gene Expression", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 785, "total_pages": 79, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gene+Expression&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gene+Expression&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T10:34:21.408Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01466504", "title": "Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Colorectal Carcinoma" ], "interventions": [ { "name": "skin punch biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2011-05", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2013-04-15", "last_synced_at": "2026-11-11T10:34:21.408Z", "location_count": 2, "location_summary": "Lebanon, New Hampshire • White River Junction, Vermont", "locations": [ { "city": "Lebanon", "state": "New Hampshire" }, { "city": "White River Junction", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT01466504" }, { "nct_id": "NCT05041257", "title": "Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "Mirvetuximab soravtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 79, "start_date": "2021-10-19", "completion_date": "2024-12-12", "has_results": true, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-11-11T10:34:21.408Z", "location_count": 11, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Covington", "state": "Louisiana" }, { "city": "Teaneck", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05041257" }, { "nct_id": "NCT02321501", "title": "Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ALK Positive", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "ROS1 Gene Rearrangement", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Ceritinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2016-06-22", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-11-11T10:34:21.408Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02321501" }, { "nct_id": "NCT06061341", "title": "TruGraf Liver Gene Expression Serial Test", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Autoimmune Liver Disease", "Autoimmune Hepatitis", "Primary Sclerosing Cholangitis", "Primary Biliary Cirrhosis" ], "interventions": [ { "name": "TruGraf®", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2024-08-01", "completion_date": "2025-12-03", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-11-11T10:34:21.408Z", "location_count": 2, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06061341" }, { "nct_id": "NCT01396239", "title": "Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "AVI-4658 (Eteplirsen)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sarepta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "13 Years", "sex": "MALE", "summary": "7 Years to 13 Years · Male only" }, "enrollment_count": 12, "start_date": "2011-07", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2020-03-30", "last_synced_at": "2026-11-11T10:34:21.408Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01396239" }, { "nct_id": "NCT00872300", "title": "PHA-739358 for the Treatment of Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "PHA-739358", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nerviano Medical Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 7, "start_date": "2008-10", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2014-05-28", "last_synced_at": "2026-11-11T10:34:21.408Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Chicago, Illinois", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00872300" }, { "nct_id": "NCT02587650", "title": "Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ALK Fusion Protein Expression", "BRAF wt Allele", "Invasive Skin Melanoma", "MET Fusion Gene Positive", "NRAS wt Allele", "NTRK1 Fusion Positive", "NTRK2 Fusion Positive", "NTRK3 Fusion Positive", "RET Fusion Positive", "ROS1 Fusion Positive", "Stage III Cutaneous Melanoma", "Stage IIIA Cutaneous Melanoma", "Stage IIIB Cutaneous Melanoma", "Stage IIIC Cutaneous Melanoma", "Stage IV Cutaneous Melanoma" ], "interventions": [ { "name": "Capmatinib", "type": "DRUG" }, { "name": "Ceritinib", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2015-03-26", "completion_date": "2018-07-12", "has_results": true, "last_update_posted_date": "2020-01-27", "last_synced_at": "2026-11-11T10:34:21.408Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02587650" }, { "nct_id": "NCT01727999", "title": "Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Immune Thrombocytopenia" ], "interventions": [], "intervention_types": [], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 75, "start_date": "2012-07", "completion_date": "2017-02", "has_results": false, "last_update_posted_date": "2017-04-26", "last_synced_at": "2026-11-11T10:34:21.408Z", "location_count": 2, "location_summary": "Stanford, California • New York, New York", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01727999" }, { "nct_id": "NCT00280527", "title": "Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Obesity" ], "interventions": [], "intervention_types": [], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 43, "start_date": "2006-09", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2011-12-20", "last_synced_at": "2026-11-11T10:34:21.408Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00280527" }, { "nct_id": "NCT06119581", "title": "A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Neoplasm Metastasis" ], "interventions": [ { "name": "LY3537982", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1264, "start_date": "2023-12-21", "completion_date": "2031-01", "has_results": false, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-11T10:34:21.408Z", "location_count": 87, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06119581" } ] }